论文部分内容阅读
目的观察安宫牛黄丸联合脑苷肌肽及常规疗法治疗重症手足口病的临床疗效。方法将86例重症手足口病患儿随机分为治疗组与对照组,每组43例。两组均予常规抗病毒、降颅压治疗,治疗组同时加用安宫牛黄丸保留灌肠及静脉滴注脑苷肌肽。两组疗程均为10天,观察临床疗效、症状体征复常及住院时间、神经功能评分情况。结果①治疗组、对照组总有效率分别为95.3%和74.4%,组间临床疗效差异有统计学意义(P<0.05)。②两组比较,临床症状体征复常时间及住院时间差异有统计学意义(P<0.05)。③治疗前后组内比较,两组神经功能评分差异有统计学意义(P<0.05);组间治疗后比较,神经功能评分差异有统计学意义(P<0.05)。结论安宫牛黄丸联合脑苷肌肽可提高小儿手足口病的临床疗效,缩短患儿临床症状体征复常时间及住院时间,降低神经功能评分,预防患儿神经系统后遗症。
Objective To observe the clinical efficacy of Angong Niuhuang Pill combined with cerebroside and conventional therapy in the treatment of severe hand-foot-mouth disease. Methods Eighty-six children with severe HFMD were randomly divided into treatment group and control group, with 43 cases in each group. Both groups were routine anti-virus, reducing intracranial pressure treatment, the treatment group also added Angong Niuhuang Wan retention enema and intravenous inosine carnosine. The two groups of treatment were 10 days, observe the clinical efficacy, symptoms and signs of normal and hospital stay, neurological score. Results ① The total effective rates of the treatment group and the control group were 95.3% and 74.4%, respectively. There were significant differences in clinical efficacy between the two groups (P <0.05). ②Compared with the two groups, the clinical symptoms and signs of recurrent time and hospital stay difference was statistically significant (P <0.05). (3) There were significant differences in neurological function scores between the two groups before and after treatment (P <0.05). There were significant differences in neurological function scores between the two groups after treatment (P <0.05). Conclusions Angong Niuhuang Pill combined with cerebroside can improve the clinical curative effect of hand-foot-mouth disease in children, shorten the time of normalization and hospital stay of clinical symptoms and signs, reduce the score of neurological function and prevent the neurological sequelae in children.